Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020
On August 11, 2020, Osmotica Pharmaceuticals plc (Nasdaq: OSMT) will release its 2020 second quarter financial results following the close of U.S. markets. A conference call led by CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn is scheduled for 4:30 p.m. ET, providing insights into the company's financial performance. Osmotica is focused on developing specialty products for underserved patient populations, boasting a diverse portfolio that includes four promoted products and about 30 non-promoted products.
- Osmotica's diverse portfolio includes four promoted products and approximately 30 non-promoted products targeting underserved markets.
- The company operates in the U.S., Argentina, and Hungary, expanding its market reach.
- None.
BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 second quarter financial results on Tuesday, August 11, 2020, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Tuesday, August 11, 2020 | ||
| Time | 4:30 p.m. ET | ||
| Toll free (U.S.) | (866) 672-5029 | ||
| International | (409) 217-8312 | ||
| Conference ID | 5287688 | ||
| Webcast (live and replay) | www.osmotica.com under the “Investor & News” section |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of four promoted products and approximately 30 non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will Osmotica Pharmaceuticals announce its Q2 2020 financial results?
What time is the Osmotica Pharmaceuticals conference call?
How can I access the Osmotica Pharmaceuticals conference call?
What is Osmotica Pharmaceuticals' focus area?
